Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
DexCom, Inc. DXCM
$121.35
+$0.28 (0.23%)
На 18:00, 12 мая 2023
-42.04%
Потенциал через год
Ранг: 2
Ключевые показатели
-
Marketcap
47026061340.00000000
-
week52high
126.44
-
week52low
66.89
-
Revenue
2909800000
-
P/E TTM
483
-
Beta
1.15328700
-
EPS
0.71000000
-
Last Dividend
0.00000000
-
Next Earnings Date
26 июл 2023 г. в 10:59
Описание компании
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include DexCom G6, an integrated CGM system for diabetes management; Dexcom Real-Time API, which enables invited third-party developers to integrate real-time CGM data into their digital health applications and devices; Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions; and Dexcom Share, a remote monitoring system. The company's products candidature comprises Dexcom G7, a next generation G7 CGM system. DexCom, Inc. has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop blood-based or interstitial glucose monitoring products. The company markets its products directly to endocrinologists, physicians, and diabetes educators. DexCom, Inc. was incorporated in 1999 and is headquartered in San Diego, California.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| Raymond James | Outperform | Outperform | 01 авг 2022 г. |
| Piper Sandler | Overweight | Overweight | 29 июл 2022 г. |
| Morgan Stanley | Equal-Weight | Equal-Weight | 29 июл 2022 г. |
| Bernstein | Outperform | 15 июл 2022 г. | |
| BTIG | Buy | Buy | 24 июн 2022 г. |
| Stifel | Buy | Buy | 07 окт 2022 г. |
| Piper Sandler | Overweight | Overweight | 07 окт 2022 г. |
| Barclays | Equal-Weight | 18 окт 2022 г. | |
| Jefferies | Buy | 12 окт 2022 г. | |
| Morgan Stanley | Equal-Weight | Equal-Weight | 11 окт 2022 г. |
| BTIG | Buy | Buy | 10 окт 2022 г. |
| Wells Fargo | Overweight | Overweight | 28 окт 2022 г. |
| Raymond James | Outperform | Outperform | 28 окт 2022 г. |
| Morgan Stanley | Equal-Weight | Equal-Weight | 28 окт 2022 г. |
| Morgan Stanley | Equal-Weight | Equal-Weight | 06 янв 2023 г. |
| Citigroup | Buy | Buy | 12 дек 2022 г. |
| Wolfe Research | Outperform | 26 янв 2023 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Покожие компании
Новостная лента
компании
Insider Summary
Insider Summary
| Reporting Name | Acquistion/Disposition | Owned | Transacted | Transaction Date |
|---|---|---|---|---|
| SAYER KEVIN R | D | 369801 | 9151 | 30 янв 2023 г. |
| SAYER KEVIN R | D | 378952 | 47693 | 30 янв 2023 г. |
| Regan Barry J. | D | 59386 | 2213 | 30 янв 2023 г. |
| Pacelli Steven Robert | D | 136876 | 412 | 23 янв 2023 г. |
| SAYER KEVIN R | D | 426645 | 45607 | 20 янв 2023 г. |
| SAYER KEVIN R | A | 472252 | 90720 | 18 янв 2023 г. |
| Pacelli Steven Robert | D | 137288 | 412 | 23 дек 2022 г. |
| Flynn Paul R | D | 55744 | 8988 | 08 дек 2022 г. |
| Stern Sadie | D | 68384 | 3844 | 21 ноя 2022 г. |
| Regan Barry J. | D | 61599 | 3781 | 21 ноя 2022 г. |
Institutional Ownership
Institutional Ownership
| Holder | Shares | Change | Date Reported |
|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 2600840 | -24482 | 31 авг 2020 г. |
| Vanguard 500 Index Fund | 1895130 | -3774 | 31 авг 2020 г. |
| Invesco QQQ Trust | 1053350 | 16186 | 31 авг 2020 г. |
| SPDR S&P 500 ETF | 973358 | -4648 | 31 авг 2020 г. |
| Fidelity Contrafund | 2295640 | -63377 | 31 июл 2020 г. |
| Vanguard Mid-Cap Index Fund | 2265300 | -18073 | 31 июл 2020 г. |
| JPMorgan Large Cap Growth Fund | 1356900 | 0 | 31 июл 2020 г. |
| T. Rowe Price New Horizons Fund | 1715060 | -835100 | 30 июн 2020 г. |
| Morgan Stanley Institutional Growth Portfolio | 1053020 | -157821 | 30 июн 2020 г. |
| Harbor Capital Appreciation Fund | 879992 | 297887 | 30 июн 2020 г. |
Новостная лента
Dexcom Shows Strength As Glucose Monitor Attracts Buyers
Investors Business Daily
11 мая 2023 г. в 13:25
Dexcom stock rebounds as glucose monitor maker sees expanding market. The med tech raised revenue guidance in its Q1 earnings report.
3 HealthTech Stocks to Watch as Digital Health Transforms the Industry
InvestorPlace
04 мая 2023 г. в 12:40
Increasingly, technologies other than drugs are working to improve patient health. From diagnostic systems like MRIs and CAT scans to high-tech glucose monitoring systems to devices that destroy tumors, medicine makes use of many such technologies.
Is Dexcom a Good Stock to Buy Now?
The Motley Fool
02 мая 2023 г. в 05:14
Dexcom recently reported results from the first quarter of 2023 and reactions were mixed. Wall Street analysts cheered but shares of Dexcom fell a couple of percentage points.
DexCom (DXCM) Q1 Earnings Beat Estimates, Volumes Remain Strong
Zacks Investment Research
28 апр 2023 г. в 12:56
DexCom's (DXCM) first-quarter 2023 results reflect strong domestic and international revenue growth on the back of its real-time Continuous Glucose Monitoring system.
DexCom (DXCM) Q1 Earnings and Revenues Beat Estimates
Zacks Investment Research
27 апр 2023 г. в 19:01
DexCom (DXCM) came out with quarterly earnings of $0.17 per share, beating the Zacks Consensus Estimate of $0.15 per share. This compares to earnings of $0.08 per share a year ago.